Shicheng Guo
@shihcheng.bsky.social
New study: SGLT2 inhibition with dapagliflozin reduces heart failure risk in type 2 diabetes, even with pathogenic variants in cardiomyopathy genes. #HeartHealth PMID:42260102, Nat Med 2026, @NatureMedicine @broadinstitute https://doi.org/10.1038/s41591-026-04439-x #Medsky #Pharmsky #RNA #ASHG 🧪